Tamtam Try Tamtam free
Springer Nature logo

Springer Nature account plan

Publishing academic knowledge

At a glance

Springer Nature, the Berlin research, health and education publisher of Nature and over 3,000 journals: €1,926.4m 2025 revenue, around 9,500 staff.

Springer Nature publishes research journals and books (including Nature, Scientific Reports and BMC), health information for medical professionals and Macmillan Education learning materials. Its customers are academic, government and corporate libraries, research funders and authors, pharmaceutical companies, healthcare professionals, schools and governments, and more than 53% of its primary research is published open access. 2025 revenue was €1,926.4m with underlying growth of 6.2%, adjusted operating profit (AOP) €543.6m and a net result of €356.0m. It has around 9,500 employees in more than 40 countries. A KGaA registered in Berlin and listed in Frankfurt since October 2024, it is controlled through its General Partner by Holtzbrinck and funds advised by BC Partners; Frank Vrancken Peeters is CEO.

Business units

Strategic priorities

Drive the transition to open access
Open access is called the main driver of growth; 19 new transformative agreements in H1 2026 took the total to more than 100, covering more than 4,400 institutions, with the US the main remaining opportunity.
Technology and AI in publishing
Over 60% of submissions ran through the SNAPP platform in 2026, nearly 60 AI assists are implemented, and the company plans investment in agentic AI while keeping a human in the loop.
New AI revenue
Nature Research Assistant had about 25,000 beta users with a commercial launch planned for early 2027, and ARC3 licenses AI-ready content as an extension of text and data mining.
Margin expansion
The company is committed to grow AOP ahead of revenue and is on track to reach its mid-term target of 100bps margin improvement one year early.
Research integrity
75 dedicated staff and about 20 AI checks per paper screen for image manipulation, fake references, fabricated text and paper-mill patterns.
Portfolio focus
Consumer Media (Scientific American and Spektrum) was sold in 2026; capital goes to organic growth, value-accretive M&A in portfolio expansion and AI, and a progressive dividend.

Latest results

In H1 2026 revenue was €939.8m, up 1.5% reported and 6.2% underlying, and AOP rose to €246.2m (+7.7% underlying) with a group AOP margin of 26.2%. Research led with underlying revenue growth of 7.2%, article publication growth of 13% and submissions up 30%, while Health grew 1.3% and Education 3.5% underlying. The net result fell to €101.3m from €129.2m on a weaker financial result. Free cash flow rose to €267.6m and leverage fell to 1.6x. Guidance was raised to underlying revenue growth of around 6% in 2026 and an underlying AOP margin increase of at least 30 basis points.

Investments and deals

Content and platform investment
Investment in intangible assets, property and content was €146.6m in 2025, including €45.7m on eBooks and databases in Research and €23.2m on Education content; technology and talent investment totals €188 million since 2021.
New journals
50 new journals were launched in 2025 and 39 in H1 2026, with Nature Books launched in July 2026.
Refinancing
€500.0m of promissory loan notes were issued in November 2025 to partly repay term loan B, cutting 2025 interest expenses to €104.5m from €156.4m.
Consumer Media divestment
Scientific American was sold in June 2026 and Spektrum der Wissenschaft closed in July 2026, described as not a core area of strategic focus.
Shareholder returns
A €0.83 per share dividend (€165.1m) was paid in 2026 and a five-year buyback authorisation was proposed for excess capital.

Challenges and risks

Public funding and US policy
Research and education budgets face fiscal pressure; the US is about 25% of revenue and 12% of articles, and NIH proposals to cap APC contributions are a stated risk.
AI disruption and misuse
New entrants or changed researcher behaviour could disrupt publishing, bad actors use AI to abuse it, and AI-related copyright litigation is a regulatory risk.
Scaling peer review
Submissions grew 30% in H1 2026, making it harder to find enough editors and reviewers and to hold turnaround times.
Weak pharma and education markets
Pharma marketing spend cuts hit Health's scientific writing services, and Education faced funding constraints and postponed curricula in South Africa and currency effects in Argentina and India.
Currency
A weaker US dollar weighed on 2025 reported figures, and the FX headwind was around 33bps on the H1 2026 margin.

What leadership says

“At the moment, we don't see a slowdown.”

Frank Vrancken Peeters, Chief Executive Officer · On submissions, H1 2026 results conference call, 5 August 2026

“Europe is essentially fully covered by TA's”

Frank Vrancken Peeters, Chief Executive Officer · FY 2025 results conference call, 17 March 2026

“I don't think it's being cautious. I think it's just being realistic.”

Frank Vrancken Peeters, Chief Executive Officer · On 2026 guidance, FY 2025 results conference call, 17 March 2026

“truly committed to grow our AOP ahead of revenue”

Alexandra Dambeck, Chief Financial Officer · H1 2026 results conference call, 5 August 2026

Where a supplier can help

Editorial workflow automation
Tied to the scaling peer review challenge and the AI priority: reviewer-finding, screening and production automation help absorb 30% submission growth without longer turnaround times.
Research integrity tooling
Tied to the research integrity priority: image forensics, reference checks and paper-mill detection extend the about 20 AI checks run on each paper.
AI content licensing infrastructure
Tied to the new AI revenue priority: attribution, provenance and secure delivery infrastructure support ARC3 and agreements such as OpenEvidence.
Institutional sales in the US
Tied to the open access priority: account intelligence and contract tooling help convert US libraries to transformative agreements, where around half of 40 active discussions sit.
Corporate research customers
Tied to the text and data mining growth in Research: corporates fund two thirds of global R&D but are less than a fifth of Research revenue, an opening for corporate go-to-market partners.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Springer Nature?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Springer Nature

What does Springer Nature do?

Springer Nature publishes research journals and books, including Nature and Scientific Reports, provides information and education for healthcare professionals, and sells Macmillan Education learning materials.

What is Springer Nature's revenue?

2025 revenue was €1,926.4m with 6.2% underlying growth and AOP of €543.6m. H1 2026 revenue was €939.8m.

How many employees does Springer Nature have?

Around 9,500 employees (9,424 FTEs) in more than 40 countries at 31 December 2025.

What is Springer Nature's strategy?

Four priorities: driving the transition to open access, harnessing technology and AI alongside domain expertise, being a place where skilled colleagues thrive, and enhancing business performance while growing responsibly.

Who leads Springer Nature?

Frank Vrancken Peeters is Chair of the Management Board and CEO; Dr Stefan von Holtzbrinck chairs the Supervisory Board. CFO Alexandra Dambeck was due to leave at the end of September 2026.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)